A study found that Repatha® (evolocumab) significantly reduced LDL cholesterol in patients with and without elevated triglycerides compared to placebo and Zetia® (ezetimibe). Learn more about the differences among LDL, HDL and triglycerides from the American Heart Association. Read more.
A study published in the New England Journal of Medicine found that Repatha® (evolocumab) reduced LDL cholesterol levels by 61 percent from pretreatment levels, and this reduction was sustained through 48 weeks. Patients taking evolocumab also showed a reduction in the rate of cardiovascular events. Learn more about the differences among LDL, HDL and triglycerides […]
A study published in BMC Medicine found that the anti-PCSK9 antibodies Repatha® (evolocumab) and Praluent® (alirocumab) reduced the LDL (bad) cholesterol level by over 50 percent, increased the HDL (good) cholesterol level, and resulted in favorable changes in other lipids. As some patients cannot tolerate statins, there is a need for alternative treatments that lower […]
A study in the American Journal of Managed Care found that reductions in the use of specialty drugs in rheumatoid arthritis, cancer and multiple sclerosis are generally associated with higher cost sharing, though the effects vary by disease type. Read more
The Institute for Patient Access (IFPA) review of Medicare data for patients with rheumatoid arthritis (RA), Crohn’s disease or immunodeficiency found that concerns about the negative consequences of non-medical switching are warranted. Specifically, they concluded that non-medical switching can negatively impact patient care and increase healthcare expenses, particularly for RA patients. Read more.